Pearl Therapeutics

Pearl, which is now a member of the AstraZeneca Group, was founded in 2006, with a mission and vision to develop differentiated therapeutics for widely prevalent respiratory disease conditions, including chronic obstructive pulmonary disease (COPD), by utilising a proprietary drug delivery platform and existing therapeutic agents administered in metered-dose inhalers (MDIs).

 

In 2007, Pearl began the development of leading product candidates with initial venture funding from 5AM Ventures, Clarus Ventures and New Leaf Ventures. In 2010, Vatera Healthcare Partners joined Pearl as a fourth investor. Between 2007-2013, Pearl’s four investors backed it with $167.5 million, allowing the progression of key therapeutic areas.

Subsequently, in 2013, AstraZeneca acquired Pearl to expand and strengthen its respiratory products portfolio, which includes many Pearl legacy compounds, and have made strides in bringing therapies to asthma patients.

Notably, Pearl’s lead combination medicine was recently launched in the US during the first quarter of 2017 and has regulatory submission acceptance in EU for COPD. Thanks to the Pearl team’s experience as inhalation product development experts, another lead product candidate is progressing through the pipeline as a potential treatment for COPD and asthma.


Pearl successfully delivered valuable therapeutics for a range of respiratory patients. As part of the AstraZeneca Group, we will continue the ongoing commitment to progress developments and innovation in respiratory science.

Colin Reisner Head of Respiratory Global Medicines Development and CEO of Pearl Therapeutics

AstraZeneca's Respiratory & Immunology pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.


Respiratory & Immunology (as at 30 July 2020)

Phase I

Phase I

  • AZD0284 psoriasis/respiratory
  • AZD0449 asthma
  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD8154 asthma
  • MEDI5117 China rheumatoid arthritis

Phase II

Phase II

  • abediterol asthma/chronic obstructive pulmonary disease
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • brazikumab ulcerative colitis
  • MEDI3506 COPD/atopic dermatitis/asthma/COVID-19
  • navafenterol chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis
  • tezepelumab chronic obstructive pulmonary disease
  • velsecorat asthma/chronic obstructive pulmonary disease

Phase III

Phase III

  • anifrolumab TULIP systemic lupus erythematosus
  • AZD1222 (ChAdOx1 nCoV-19) COVID vaccine
  • Bevespi Aerosphere (PT003) chronic obstructive pulmonary disease
  • brazikumab crohns disease
  • Breztri Aerosphere (PT010) chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • nirsevimab passive RSV immunisation
  • PT027 asthma
  • tezepelumab NAVIGATOR SOURCE severe uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri (PT010) asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra NATRON hypereosinophilic syndrome
  • Fasenra OSTRO ORCHID (Japan/China) nasal polyposis
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma